ChromaDex Co. (NASDAQ:CDXC) Short Interest Down 5.4% in September

ChromaDex Co. (NASDAQ:CDXC) saw a large decline in short interest in September. As of September 15th, there was short interest totalling 2,950,000 shares, a decline of 5.4% from the August 31st total of 3,120,000 shares. Approximately 6.2% of the shares of the stock are short sold. Based on an average trading volume of 387,800 shares, the days-to-cover ratio is presently 7.6 days.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Roth Mkm reissued a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a report on Wednesday, June 12th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of ChromaDex in a report on Friday, August 9th.

Insider Buying and Selling

In other news, Director Kristin Patrick sold 23,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 9.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. WINTON GROUP Ltd acquired a new stake in ChromaDex during the second quarter worth approximately $597,000. Bank of New York Mellon Corp boosted its stake in ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of ChromaDex in the 2nd quarter worth approximately $124,000. Perritt Capital Management Inc. bought a new stake in shares of ChromaDex in the 1st quarter worth approximately $139,000. Finally, Renaissance Technologies LLC raised its holdings in ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after acquiring an additional 32,400 shares during the period. 15.41% of the stock is owned by institutional investors and hedge funds.

ChromaDex Stock Down 3.9 %

CDXC traded down $0.15 during trading on Monday, hitting $3.65. The company’s stock had a trading volume of 343,618 shares, compared to its average volume of 304,019. The stock has a market capitalization of $275.72 million, a price-to-earnings ratio of -73.00 and a beta of 1.86. ChromaDex has a 12 month low of $1.25 and a 12 month high of $4.65. The firm’s 50 day moving average price is $3.27 and its two-hundred day moving average price is $3.23.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.